Skip to Main Content

CHAPTER SUMMARY FROM THE PHARMACOTHERAPY HANDBOOK

For the Chapter in the Schwinghammer, Handbook (not Wells Handbook anymore) please go to Chapter 79, Chronic Obstructive Pulmonary Disease.

KEY CONCEPTS

KEY CONCEPTS

  • image Chronic obstructive pulmonary disease (COPD) is a treatable and preventable disease characterized by progressive airflow limitation that is not fully reversible and is associated with an abnormal inflammatory response of the lungs to noxious particles or gases.

  • image Mortality from COPD has increased steadily over the past three decades; it currently is the fourth leading cause of death in the United States.

  • image The primary cause of COPD is cigarette smoking, implicated in 85% of diagnosed cases in the United States. Other risks include a genetic predisposition, environmental exposures (including occupational dusts and chemicals), and air pollution.

  • image In patients with COPD, staging of airflow limitation (GOLD 1-4) is classified by spirometry measurements, while disease severity (Category A-D) is classified using a combined assessment of symptom score, as measured by validated questionnaire, and risk for future exacerbations.

  • image Smoking cessation and avoidance of other known toxins are the only management strategies proven to slow the progression of COPD.

  • image Oxygen therapy has been shown to reduce mortality in selected patients with COPD. Oxygen therapy is indicated for patients with a resting PaO2 of less than 55 mm Hg (7.3 kPa) or a PaO2 of less than 60 mm Hg (8.0 kPa) and evidence of right-sided heart failure, polycythemia, or impaired neurologic function.

  • image Inhaled bronchodilators are the mainstay of drug therapy for COPD and are used to relieve patient symptoms, improve exercise tolerance and quality of life. Guidelines recommend short-acting bronchodilators as initial therapy for patients with occasional symptoms and for all patients as rescue therapy for the relief of symptoms.

  • image For patients experiencing persistent symptoms, either a long-acting β2-agonist (LABA) or long-acting anticholinergic (LAMA) offers significant benefits and both are of comparable efficacy. If a patient has continued symptoms, combining long-acting bronchodilator agents (LABA plus LAMA) is recommended.

  • image For patients at high risk for future exacerbations, either a long-acting β2-agonist (LABA) or long-acting anticholinergic (LAMA) are effective at reducing exacerbation frequency. Anticholinergic agents are more effective at reducing exacerbation frequency and should be considered first-line. If a patient has continued exacerbations or has more severe disease (Category D) combining long-acting bronchodilator agents (LABA plus LAMA) is recommended.

  • image The role of inhaled corticosteroid (ICS) therapy in COPD is controversial. Patients with frequent and severe exacerbations may benefit from ICS therapy, although the risk of pneumonia is increased.

  • image Acute exacerbations of COPD have a significant impact on disease progression and mortality. Treatment of acute exacerbations includes intensification of bronchodilator therapy and a short course of systemic corticosteroids.

  • image Antimicrobial therapy should generally be used during acute exacerbations of COPD if the patient exhibits at least two of the following: increased dyspnea, increased sputum volume, and increased sputum purulence. A C-reactive protein (CRP) test may be ...

Pop-up div Successfully Displayed

This div only appears when the trigger link is hovered over. Otherwise it is hidden from view.